The Short and Sweet on Sodium-Glucose Cotransporter Inhibitors and Glucagon-like Peptide-1 Receptor Agonists in Heart Failure.

An ad hoc analysis of the FIGHT trial examined first and recurrent events of HFH or all-cause death, revealing a positive trend towards increased total HFH or all-cause death (HR 1.53, 95% CI [1.02–2.31]; p=0.040), use of IV diuretic therapy, and total arrhythmias reported by investigators in the liraglutide cohort. 87 A subsequent multicenter, double-blind, randomized trial, the LIVE Study, enrolled 241 patients with reduced LVEF ≤45% and NYHA class I–III.

also in 11,005 other papers

86 Additionally, secondary endpoints, such as HFH or urgent medical visits for HF (HR 0.79 95% CI [0.60–1.03]), were numerically lower but did not reach statistical significance.

also in 111,027 other papers